EP Patent

EP4466022A4 — Pharmaceutical formulations and methods for the treatment of metabolic and liver diseases

Assigned to Viking Therapeutics Inc · Expires 2025-12-10 · 0y expired

What this patent protects

Patent listed against Mounjaro.

Drugs covered by this patent

Patent Metadata

Patent number
EP4466022A4
Jurisdiction
EP
Classification
Expires
2025-12-10
Drug substance claim
No
Drug product claim
No
Assignee
Viking Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.